Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Specialty & Advanced Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:EGRX
- CUSIP: N/A
- Web: www.eagleus.com
Capitalization:- Market Cap: $1.15043 billion
- Outstanding Shares: 15,298,000
Average Prices:- 50 Day Moving Avg: $76.50
- 200 Day Moving Avg: $77.91
- 52 Week Range: $42.33 - $97.15
P/E:- Trailing P/E Ratio: 11.44
- Foreward P/E Ratio: 15.10
- P/E Growth: 1.37
Sales & Book Value:- Annual Revenue: $236.68 million
- Price / Sales: 4.71
- Book Value: $10.94 per share
- Price / Book: 6.65
Profitability:- EBIDTA: $90.92 million
- Net Margins: 44.48%
- Return on Equity: 79.25%
- Return on Assets: 57.28%
Debt:- Current Ratio: 3.49%
- Quick Ratio: 3.40%
Misc:- Average Volume: 361,162 shs.
- Beta: 1.48
- Short Ratio: 8.36
Frequently Asked Questions for Eagle Pharmaceuticals (NASDAQ:EGRX)
What is Eagle Pharmaceuticals' stock symbol?
Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."
How were Eagle Pharmaceuticals' earnings last quarter?
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced its earnings results on Monday, May, 8th. The company reported $1.42 EPS for the quarter, missing the consensus estimate of $1.44 by $0.02. The company had revenue of $76.80 million for the quarter, compared to analysts' expectations of $70.10 million. Eagle Pharmaceuticals had a net margin of 44.48% and a return on equity of 79.25%. The business's quarterly revenue was up 159.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.06) earnings per share. View Eagle Pharmaceuticals' Earnings History.
Where is Eagle Pharmaceuticals' stock going? Where will Eagle Pharmaceuticals' stock price be in 2017?
4 brokers have issued 12-month target prices for Eagle Pharmaceuticals' stock. Their predictions range from $57.00 to $118.00. On average, they anticipate Eagle Pharmaceuticals' stock price to reach $91.50 in the next twelve months. View Analyst Ratings for Eagle Pharmaceuticals.
What are analysts saying about Eagle Pharmaceuticals stock?
Here are some recent quotes from research analysts about Eagle Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. " (7/10/2017)
- 2. Mizuho analysts commented, "We remain cautious on 2017 revenue, the exertional heat stroke (EHS) launch, and lower takeout probability: Eagle reported 4Q:16 revs of $81.1M and GAAP EPS of $3.52 vs. FactSet consensus $86.0M and $2.82. Mgmt introduced FY:17 SG&A guidance of $65-$68M and $31-$35M in R&D. Consensus models are in line with these expense ranges, but we think that 2017 revenue expectations (particularly Ryanodex) need to come down based on a slower EHS ramp. Because we now have a better appreciation for the hurdles associated with this launch, we also lowered our probability of takeout to 40%, from 50% previously. On a standalone basis, we think that EGRX is only worth $54/share so the stock already reflects expectations of a takeout, in our view. We reiterate our Underperform rating and $66 PT, which are based on a weighted blend of DCF ($54) and SOTP ($85) valuations." (3/17/2017)
Who are some of Eagle Pharmaceuticals' key competitors?
Some companies that are related to Eagle Pharmaceuticals include Indivior PLC (INDV), Supernus Pharmaceuticals (SUPN), Advanced Accelerator Applications S.A. (AAAP), Repligen Corporation (RGEN), TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Aimmune Therapeutics (AIMT), Rockwell Medical (RMTI), Assembly Biosciences (ASMB), Novan (NOVN), Check-Cap (CHEK), CorMedix (CRMD), DARA Biosciences (DARA), Macrocure Ltd (MCUR) and Salix Pharmaceuticals (SLXP).
Who are Eagle Pharmaceuticals' key executives?
Eagle Pharmaceuticals' management team includes the folowing people:
- Michael Graves, Independent Chairman of the Board
- Scott L. Tarriff, Chief Executive Officer, Independent Director
- Pete A. Meyers, Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
- David E. Riggs, Chief Financial Officer
- Steven L. Krill Ph.D., Executive Vice President, Chief Scientific Officer
- Adrian J. Hepner M.D. Ph.D, Executive Vice President, Chief Medical Officer
- Douglas L. Braunstein, Independent Director
- Richard A. Edlin, Independent Director
- Sander A. Flaum, Independent Director
- Robert L. Glenning, Independent Director
Who owns Eagle Pharmaceuticals stock?
Eagle Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Hershey Trust Co. (0.10%), James Investment Research Inc. (0.09%), Fisher Asset Management LLC (0.07%), Aperio Group LLC (0.02%), Louisiana State Employees Retirement System (0.02%) and Capstone Asset Management Co. (0.02%). Company insiders that own Eagle Pharmaceuticals stock include David Pernock, Michael Graves, Pete A Meyers, Proquest Investments Iv, LP, Proquest Management Llc, Richard A Edlin, Sander A Flaum, Sander A Flaum, Scott Tarriff, Steven B Ratoff and Steven L Krill. View Institutional Ownership Trends for Eagle Pharmaceuticals.
Who sold Eagle Pharmaceuticals stock? Who is selling Eagle Pharmaceuticals stock?
Eagle Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Capstone Asset Management Co. and Louisiana State Employees Retirement System. Company insiders that have sold Eagle Pharmaceuticals stock in the last year include Proquest Investments Iv, LP, Sander A Flaum, Steven B Ratoff and Steven L Krill. View Insider Buying and Selling for Eagle Pharmaceuticals.
Who bought Eagle Pharmaceuticals stock? Who is buying Eagle Pharmaceuticals stock?
Eagle Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Hershey Trust Co., James Investment Research Inc., Aperio Group LLC, Fisher Asset Management LLC, Bank of Montreal Can and State of Alaska Department of Revenue. Company insiders that have bought Eagle Pharmaceuticals stock in the last two years include David Pernock, Michael Graves, Pete A Meyers and Richard A Edlin. View Insider Buying and Selling for Eagle Pharmaceuticals.
How do I buy Eagle Pharmaceuticals stock?
Shares of Eagle Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eagle Pharmaceuticals' stock price today?
One share of Eagle Pharmaceuticals stock can currently be purchased for approximately $72.80.
MarketBeat Community Rating for Eagle Pharmaceuticals (NASDAQ EGRX)MarketBeat's community ratings are surveys of what our community members think about Eagle Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Eagle Pharmaceuticals (NASDAQ:EGRX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | $91.50 (25.69% upside) |
Analysts' Ratings History for Eagle Pharmaceuticals (NASDAQ:EGRX)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/16/2017 | Royal Bank Of Canada | Set Price Target | Buy | $94.00 | Medium |  |
| 5/25/2017 | Mizuho | Lower Price Target | Underperform | $66.00 -> $57.00 | Low | |
| 5/9/2017 | Piper Jaffray Companies | Set Price Target | Overweight | $90.00 -> $118.00 | High | |
| 11/2/2016 | William Blair | Boost Price Target | Outperform | $83.00 -> $97.00 | N/A | |
(Data available from 7/25/2015 forward)
Earnings History for Eagle Pharmaceuticals (NASDAQ:EGRX)Earnings History by Quarter for Eagle Pharmaceuticals (NASDAQ EGRX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/8/2017 | Q1 2017 | $1.44 | $1.42 | $70.10 million | $76.80 million | View | Listen | |
| 3/1/2017 | Q416 | $2.24 | $3.52 | $86.13 million | $81.10 million | View | Listen | |
| 11/9/2016 | Q316 | $0.71 | $0.73 | $41.04 million | $37.80 million | View | Listen | |
| 8/9/2016 | Q216 | $0.71 | $0.80 | $43.55 million | $40.90 million | View | N/A | |
| 5/9/2016 | Q116 | $0.46 | ($0.06) | $29.07 million | $29.60 million | View | N/A | |
| 2/25/2016 | Q415 | $0.53 | $0.07 | $20.78 million | $18.20 million | View | Listen | |
| 11/11/2015 | Q315 | ($0.56) | ($0.65) | $5.07 million | $3.30 million | View | Listen | |
| 8/11/2015 | Q215 | ($0.59) | ($0.53) | $4.70 million | $6.00 million | View | Listen | |
| 5/12/2015 | Q115 | $1.56 | $1.31 | $3.41 million | $36.30 million | View | Listen | |
| 12/17/2014 | Q314 | ($0.49) | ($0.65) | $2.90 million | $2.81 million | View | N/A | |
| 8/11/2014 | Q214 | ($0.39) | ($0.21) | $3.40 million | $5.80 million | View | N/A | |
| 5/14/2014 | Q114 | ($0.26) | ($0.36) | $3.20 million | $5.00 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Eagle Pharmaceuticals (NASDAQ:EGRX)2017 EPS Consensus Estimate: $3.83
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | $1.46 | $1.46 | $1.46 |
| Q2 2017 | 1 | $0.59 | $0.59 | $0.59 |
| Q3 2017 | 1 | $0.68 | $0.68 | $0.68 |
| Q4 2017 | 1 | $1.10 | $1.10 | $1.10 |
(Data provided by Zacks Investment Research)
Dividend History for Eagle Pharmaceuticals (NASDAQ:EGRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Eagle Pharmaceuticals (NASDAQ:EGRX)Insider Ownership Percentage: 19.50%
Insider Trades by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/12/2017 | Pete A Meyers | CFO | Buy | 350 | $71.49 | $25,021.50 | |
| 5/19/2017 | David Pernock | Insider | Buy | 255 | $79.69 | $20,320.95 | |
| 5/16/2017 | David Pernock | Insider | Buy | 200 | $82.24 | $16,448.00 | |
| 4/25/2017 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 54,180 | $88.38 | $4,788,428.40 | |
| 4/3/2017 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 91,332 | $83.09 | $7,588,775.88 | |
| 3/29/2017 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 106,468 | $83.01 | $8,837,908.68 | |
| 3/28/2017 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 6,182 | $83.02 | $513,229.64 | |
| 3/27/2017 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 39,431 | $83.00 | $3,272,773.00 | |
| 3/23/2017 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 1,200 | $83.05 | $99,660.00 | |
| 3/23/2017 | Steven L Krill | EVP | Sell | 14,125 | $81.07 | $1,145,113.75 | |
| 3/22/2017 | Richard A Edlin | Director | Buy | 6,000 | $79.44 | $476,640.00 | |
| 3/21/2017 | David Pernock | Insider | Buy | 61 | $83.98 | $5,122.78 | |
| 3/20/2017 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 100,000 | $82.06 | $8,206,000.00 | |
| 3/9/2017 | David Pernock | Insider | Buy | 450 | $77.84 | $35,028.00 | |
| 1/4/2017 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 65,114 | $85.16 | $5,545,108.24 | |
| 12/13/2016 | Steven B Ratoff | Director | Sell | 10,000 | $75.01 | $750,100.00 | |
| 11/28/2016 | Sander A Flaum | Director | Sell | 5,000 | $78.66 | $393,300.00 | |
| 11/11/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 34,486 | $85.15 | $2,936,482.90 | |
| 11/9/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 153,830 | $79.29 | $12,197,180.70 | |
| 11/7/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 5,030 | $75.39 | $379,211.70 | |
| 11/4/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 245,770 | $71.02 | $17,454,585.40 | |
| 9/30/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 22,100 | $70.06 | $1,548,326.00 | |
| 9/29/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 77,900 | $70.04 | $5,456,116.00 | |
| 9/21/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 99,795 | $66.17 | $6,603,435.15 | |
| 9/8/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 70,925 | $62.50 | $4,432,812.50 | |
| 8/24/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 28,870 | $63.00 | $1,818,810.00 | |
| 8/17/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 99,795 | $61.36 | $6,123,421.20 | |
| 8/16/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 60,150 | $61.67 | $3,709,450.50 | |
| 8/15/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 24,949 | $60.77 | $1,516,150.73 | |
| 5/13/2016 | Proquest Management Llc | Major Shareholder | Sell | 17,980 | $40.72 | $732,145.60 | |
| 4/1/2016 | Scott Tarriff | CEO | Sell | 30,765 | $40.63 | $1,249,981.95 | |
| 3/15/2016 | Michael Graves | Director | Buy | 1,000 | $56.73 | $56,730.00 | |
| 2/1/2016 | Scott Tarriff | CEO | Sell | 18,360 | $68.08 | $1,249,948.80 | |
| 12/22/2015 | Sander A. Flaum | Director | Sell | 13,025 | $54.81 | $713,900.25 | |
| 12/1/2015 | Scott Tarriff | CEO | Sell | 14,050 | $88.93 | $1,249,466.50 | |
| 11/2/2015 | Scott Tarriff | CEO | Sell | 19,339 | $64.63 | $1,249,879.57 | |
| 10/1/2015 | Scott Tarriff | CEO | Sell | 17,878 | $69.92 | $1,250,029.76 | |
| 9/1/2015 | Scott Tarriff | CEO | Sell | 16,245 | $76.95 | $1,250,052.75 | |
| 7/1/2015 | Scott Tarriff | CEO | Sell | 135,710 | $46.34 | $6,288,801.40 | |
| 6/16/2015 | Steven L Krill | Insider | Sell | 9,980 | $81.60 | $814,368.00 | |
| 2/18/2014 | Jay Moorin | Director | Buy | 333,333 | $15.00 | $4,999,995.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Eagle Pharmaceuticals (NASDAQ:EGRX)
Latest Headlines for Eagle Pharmaceuticals (NASDAQ:EGRX)
| Source: |
|
| Date | Headline |
|---|
 | ETFs with exposure to Eagle Pharmaceuticals, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 6:04 PM |
 | Eagle Pharmaceuticals Inc (EGRX) Given a $94.00 Price Target at Royal Bank Of Canada
www.americanbankingnews.com - July 18 at 12:56 AM |
| ETFs with exposure to Eagle Pharmaceuticals, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 3:31 PM |
| Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : July 11, 2017
finance.yahoo.com - July 11 at 7:20 PM |
| Eagle Pharmaceuticals, Inc. (EGRX) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - July 10 at 8:26 PM |
 | Eagle Pharmaceuticals' Upcoming Catalysts Provide Support For Medium-Term Play
seekingalpha.com - July 8 at 10:28 AM |
| Contrasting Eagle Pharmaceuticals (NASDAQ:EGRX) & Mallinckrodt PLC (MNK)
www.americanbankingnews.com - July 6 at 7:40 AM |
 | Top Stocks to Look For on July’s FDA Calendar
247wallst.com - July 1 at 5:49 PM |
| Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - June 30 at 11:32 PM |
| Eagle Pharmaceuticals, Inc. (EGRX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 30 at 12:32 PM |
| Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : EGRX-US : June 26, 2017
finance.yahoo.com - June 26 at 9:37 AM |
| These 3 Stocks Are Up Over 500% in the Last 3 Years
finance.yahoo.com - June 25 at 5:36 PM |
| Eagle Pharmaceuticals, Inc. (EGRX) Upgraded to "Buy" at BidaskClub
www.americanbankingnews.com - June 21 at 7:32 PM |
| ETFs with exposure to Eagle Pharmaceuticals, Inc. : June 19, 2017
finance.yahoo.com - June 19 at 6:33 PM |
 | Eagle Pharmaceuticals (EGRX) Shares Cross Above 200 DMA
www.nasdaq.com - June 19 at 1:33 PM |
| Eagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017
finance.yahoo.com - June 16 at 5:46 PM |
| Insider Buying: Eagle Pharmaceuticals, Inc. (EGRX) CFO Acquires 350 Shares of Stock
www.americanbankingnews.com - June 12 at 7:52 PM |
| What Falling Estimates & Price Mean for Eagle Pharmaceuticals (EGRX) - Nasdaq
www.nasdaq.com - June 8 at 5:55 PM |
| What Falling Estimates & Price Mean for Eagle Pharmaceuticals (EGRX)
finance.yahoo.com - June 8 at 5:54 PM |
| Eagle Pharmaceuticals Inc (EGRX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - June 5 at 9:15 AM |
 | Eagle Pharmaceuticals, Inc. to Present at Investor Conferences in June - Business Wire (press release)
www.businesswire.com - June 2 at 3:43 AM |
| Eagle Pharmaceuticals, Inc. to Present at Investor Conferences in June
finance.yahoo.com - May 31 at 4:55 PM |
| Eagle Pharmaceuticals (EGRX) Shares Cross Below 200 DMA - Nasdaq
www.nasdaq.com - May 25 at 6:52 PM |
| Eagle Pharmaceuticals' (EGRX) Underperform Rating Reaffirmed at Mizuho
www.americanbankingnews.com - May 25 at 6:48 PM |
| Eagle Pharmaceuticals Inc (EGRX) Insider Buys $20,320.95 in Stock
www.americanbankingnews.com - May 19 at 8:52 PM |
| Eagle Pharmaceuticals Inc (EGRX) Insider Purchases $16,448.00 in Stock
www.americanbankingnews.com - May 16 at 8:44 PM |
| ValuEngine Upgrades Eagle Pharmaceuticals Inc (EGRX) to "Strong-Buy"
www.americanbankingnews.com - May 16 at 4:32 PM |
 | Eagle Pharmaceuticals Inc. (EGRX) Dropped After New CFO Appointed
www.rttnews.com - May 16 at 12:40 PM |
| Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : May 16, 2017
finance.yahoo.com - May 16 at 12:39 PM |
| Eagle Pharmaceuticals Inc (EGRX) Short Interest Update
www.americanbankingnews.com - May 16 at 7:26 AM |
| Eagle Pharmaceuticals Inc. (EGRX) Is Losing Ground After New CFO Named
www.nasdaq.com - May 15 at 11:44 AM |
| Eagle Pharmaceuticals Appoints Pete A. Meyers as Chief Financial Officer
finance.yahoo.com - May 15 at 11:44 AM |
| Edited Transcript of EGRX earnings conference call or presentation 8-May-17 12:30pm GMT
finance.yahoo.com - May 12 at 5:24 PM |
| Q2 2017 EPS Estimates for Eagle Pharmaceuticals Inc (EGRX) Decreased by Analyst
www.americanbankingnews.com - May 11 at 8:50 AM |
| Eagle Pharmaceuticals Inc (EGRX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 10 at 11:54 PM |
| Eagle Pharmaceuticals, Inc. to Present at Bank of America Merrill Lynch 2017 Health Care Conference
finance.yahoo.com - May 10 at 5:03 PM |
| Eagle Pharmaceuticals Inc (EGRX) Forecasted to Post Q3 2017 Earnings of $0.68 Per Share
www.americanbankingnews.com - May 10 at 9:10 AM |
| Eagle Pharmaceuticals Inc (EGRX) Receives "Overweight" Rating from Piper Jaffray Companies
www.americanbankingnews.com - May 9 at 8:14 AM |
| Eagle Pharmaceuticals, Inc. Reports First Quarter 2017 Results
finance.yahoo.com - May 9 at 7:32 AM |
| Eagle Pharmaceuticals Inc (EGRX) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 8 at 3:36 PM |
| Eagle Pharmaceuticals, Inc. Reports First Quarter 2017 Results - Business Wire (press release)
www.businesswire.com - May 8 at 9:15 AM |
| Commit To Buy Eagle Pharmaceuticals At $75, Earn 11.3% Annualized Using Options
www.nasdaq.com - May 5 at 5:05 PM |
| Eagle Pharmaceuticals (EGRX) Given Daily News Impact Score of 0.22
www.americanbankingnews.com - May 4 at 1:21 AM |
| Eagle Pharmaceuticals Inc (EGRX) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - May 3 at 1:01 AM |
| Eagle Pharmaceuticals (EGRX) Getting Somewhat Positive Press Coverage, Analysis Shows
www.americanbankingnews.com - April 29 at 2:51 PM |
| Insider Selling: Eagle Pharmaceuticals Inc (EGRX) Major Shareholder Sells 54,180 Shares of Stock
www.americanbankingnews.com - April 27 at 9:03 PM |
| Eagle Pharmaceuticals (EGRX) Earns Media Impact Rating of 0.13
www.americanbankingnews.com - April 26 at 5:52 PM |
| Eagle Pharmaceuticals Inc (EGRX) PT Set at $86.00 by Royal Bank of Canada
www.americanbankingnews.com - April 25 at 4:18 PM |
| Eagle Pharmaceuticals, Inc. to Discuss First Quarter 2017 Financial Results on May 8, 2017
finance.yahoo.com - April 25 at 11:38 AM |
| ETFs with exposure to Eagle Pharmaceuticals, Inc. : April 24, 2017
finance.yahoo.com - April 24 at 4:45 PM |
Eagle Pharmaceuticals (EGRX) Chart for Tuesday, July, 25, 2017
